¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Chengdu Institute of Biological Products"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • fibrinogen degradation products
    ¼¶À¯¼Ò¿øºÐÇØ»ê¹°
  • biological
    »ý¹°ÇÐÀû-
  • biological assay
    »ý¹°ÇÐÀû°ËÁ¤
  • biological characteristic
    »ý¹°ÇÐÀûƯ¼º
  • biological chemistry
    »ý¹°È­ÇÐ
  • biological clock
    »ýü½Ã°è
  • biological coefficient
    »ý¹°ÇÐÀû°è¼ö
  • biological containment
    »ý¹°ÇÐÀû¿À¿°°ü¸®
  • biological diagnosis
    »ý¹°ÇÐÀûÁø´Ü
  • biological dressing
    »ý¹°ÇÐÀûµå·¹½Ì
  • biological engineering
    »ý¹°°øÇÐ
  • biological filter
    »ý¹°ÇÐÀû¿©°ú±â, »ý¹°ÇÐÀû°Å¸£°³
  • biological filtration
    »ý¹°ÇÐÀû¿©°ú, »ý¹°ÇÐÀû°Å¸£±â
  • biological half life
    »ý¹°ÇÐÀû¹Ý°¨±â
  • biological hazard
    »ý¹°ÇÐÀûÀçÇØ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • biological marker
    »ý¹°ÇÐÀûÇ¥Áö
  • fibrinogen degradation products product
    ¼¶À¯¼ÒºÐÇØ»ê¹°
  • fibrinogen degradation products product
    ¼¶À¯¼Ò¿øºÐÇØ»ê¹°
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • biological assay
    »ý¹°ÇÐÀû°ËÁ¤
  • biological
    »ý¹°ÇÐÀû-
  • biological characteristic
    »ý¹°ÇÐÆ¯¼º
  • biological chemistry
    »ý¹°È­ÇÐ
  • biological coefficient
    »ý¹°ÇÐÀû°è¼ö
  • biological containment
    »ý¹°ÇÐÀû¿À¿°°ü¸®
  • biological diagnosis
    »ý¹°ÇÐÀûÁø´Ü
  • biological dressing
    »ý¹°ÇÐÀûµå·¹½Ì
  • biological engineering
    »ýü°øÇÐ
  • biological filter
    »ý¹°ÇÐÀû°Å¸£°³
  • biological filtration
    »ý¹°ÇÐÀû°Å¸£±â
  • biological hazard
    »ý¹°ÇÐÀûÀ§ÇØ
  • biological marker
    »ý¹°ÇÐÀûÁöÇ¥
  • biological microscope
    »ý¹°Çö¹Ì°æ
  • biological preparation
    »ý¹°ÇÐÁ¦Á¦
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • advanced glycosylation end products
    ÁøÇ༺´çÈ­Á¾¸»»ý¼º¹°(òäú¼àõÓÐûùðûØÇßæà÷Úª)
  • grain products
    ¿¡¤Á°î·ùÁ¦Ç°.
  • primary biological productivity
    ÀÏÂ÷»ý¹°»ý»ê·Â(¡­ßæÚªßæß§æ³).
  • relative biological effectiveness
    »ó´ëÀû »ý¹°ÇÐÀû È¿°ú(ßÓÓßîÜßæÚªùÊîÜüù
  • relative biological effectiveness
    »ó´ë»ý¹°ÇÐÀûÈ¿°ú
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • biological products
    »ý¹°ÇÐÀû Á¦Á¦(¡­ð²ð¥).
  • biological products
    »ý¹°ÇÐÀû Á¦Á¦(ÊÙ̡̡).
  • advanced glycosylation end products
    ÁøÇ༺´çÈ­Á¾¸»»ý¼º¹°(òäú¼àõÓÐûùðûØÇßæà÷Úª)
  • fibrin degradation products =fDP
    ¼¶À¯¼ÒºÐÇØ»ê¹°
  • fibrinogen degradation products=FDP
    ¼¶À¯¼Ò¿ø ºÐÇØ»ê¹°
  • grain products
    ¿¡¤Á°î·ùÁ¦Ç°.
  • marine products
    ÇØ»ê¹°(Ì´Ë×ËÑ).
  • retarder for gypsum products
    ¼®°í»ê¹°°æÈ­Áö¿¬Á¦(à´ÍÇß§ÚªÌãûùòÀæÅð¥).
  • biologic test ; biological test
    »ý¹°ÇÐÀû ½ÃÇè(¡­ãËúÐ).
  • biological
    [¹Ì»ý,±â»ý,³»°ú,¿Ü°ú,°áÇÙ,ÀÓº´,¸é¿ª,°£È£,À¯Àü]»ý¹°ÇÐÀûÀÎ.
  • biological
    »ý¹°ÇÐÀûÀÎ
  • biological antagonism
    »ý¹°ÇÐÀû ±æÇ×(¡­±æÇ×).
  • biological antagonism
    »ý¹°ÇÐÀû ±æÇ×(¡­ÑÏù÷)
  • biological assay
    Àθí [¸é¿ª,°£È£,À¯Àü,¹Ì»ý,±â»ý,¹ÙÀÌ]»ý¹°ÇÐÀû °ËÁ¤(¡­ËþïÒ).
  • biological assay
    Àθí[¸é¿ª,°£È£,À¯Àü,¹Ì»ý,±â»ý,¹ÙÀÌ] »ý¹°ÇÐÀû ¾Æ¼¼ÀÌ(¡­ËþïÒ).
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • biological transmission
    »ý¹°ÇÐÀûÀüÆÄ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • biological assay
    »ý¹°ÇÐÀû(ßæÚªùÊîÜ) ¾Æ½êÀÌ
  • biological buffers
    »ý¹°¿ÏÃæ¾×(ßæÚªèÐõúäû)
  • biological chemistry
    »ý¹°È­ÇÐ(ßæÚªûùùÊ)
  • biological clock
    »ý¹°½Ã°è(ßæÚªãÁͪ)
  • biological evolution
    »ý¹°ÁøÈ­(ßæÚªòäûù)
  • biological half-life
    »ý¹°ÇÐÀû ¹Ý°¨±â(ßæÚªùÊîÜÚâÊõÑ¢)
  • biological nitrogen fixation
    »ý¹°ÇÐÀû Áú¼Ò°íÁ¤(ßæÚªùÊîÜòòáÈͳïÒ)
  • biological oxidation-reduction
    »ýü »êȭȯ¿ø(ßæô÷ß«ûùü½êª)
  • biological oxygen demand
    »ý¹°ÇÐÀû »ê¼Ò¿ä±¸·®(ßæÚªùÊîÜß«áÈé©Ï´Õá)
  • biological response modifier
    »ý¹°ÇÐÀû ´ëÀÀ¼ö½ÄÀÚ(ßæÚªùÊîÜÓßëëáóãÞí­)
  • biological rhythm
    »ýü(ßæô÷) ¸®µë
  • biological value
    »ý¹°°¡(ßæÚªÊ¤)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • biological characteristic
    »ý¹°ÇÐÀûƯ¼º
  • biological effect
    »ý¹°ÇÐÀûÈ¿°ú
  • biological half life
    »ý¹°ÇÐÀû¹Ý°¨±â
  • biological hazard
    »ý¹°ÇÐÀûÀ§ÇØ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
FDP(s)   1) Fibrinolytic split Products(= FSP)
  2) Fibrinogen Degradation Products
FSP familial spastic paraplegia; fibrin split products; fibrinogen split products; fine suspended partic...
ABL abetalipoproteinemia; acceptable blood loss; African Burkitt lymphoma; Albright-Butler-Lightwood [sy...
BW bacteriological warfare; bed wetting; below waist; biological warfare; biological weapon; birth weig...
AIBS American Institute of Biological Sciences
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
NIBSC National Institute for Biological Standards and Control
B.E.I. Biological Exposure Index
BI biological indicator
BNR Biological Nutrient Removal
BOD Biological Oxygen Demand
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • advanced glycosylation end products
    ÁøÇ༺ ´çÈ­ Á¾¸» »ý¼º¹°
  • National Institute of Neurological Diseaseand Blindness
    ½Å°æ Áúȯ ¹× ½Ç¸í ±¹¸³¿¬±¸¼Ò
  • The National Institute of Dental Research
    ±¹¸³ Ä¡ÀÇÇÐ ¿¬±¸¼Ò
  • U.S. National Institute of Health
    ¹Ì±¹±¹¸³°Ç°­¿¬±¸¼Ò
  • biological action
    »ý¹° ÀÛ¿ë
  • biological antagonism
    »ý¹°ÇÐÀû ±æÇ×
  • biological characteristics
    »ý¹°ÇÐÀû Ư¼º
  • biological clock
    »ý¹°ÇÐÀû ½Ã°è
  • biological diagnosis
    »ý¹°ÇÐÀû Áø´Ü
  • biological effect
    »ý¹°ÇÐÀû È¿°ú
  • biological engineering
    »ýü °øÇÐ
  • biological factor
    »ý¹°ÇÐÀû ¿äÀÎ
  • biological filtration
    »ý¹°ÇÐÀû °Å¸£±â
  • biological hazard
    »ý¹°ÇÐÀû À§ÇØ
  • biological membrane
    »ýü ¸·
    ¼¼Æ÷ ¶Ç´Â ¼¼Æ÷ ¼Ò±â°üÀÇ °ÑÀ» ½Î°í ÀÖ´Â ¸·. ¹Ì»ý¹°, ½Ä¹°, µ¿¹°ÀÇ ¼¼Æ÷¸·°ú ¿±·Ïü, ¹ÌÅäÄܵ帮¾ÆÀÇ ³», ¿Ü¸·, °ñÁöü, ¼ÒÆ÷ü ¸·, ÇÙ¸· µîÀÌ º¸±âÀÌ´Ù. »ýü¸·ÀÇ ±¸Á¶¿¡ °üÇÑ ¸ðµ¨Àº ¿©·¯ °¡Áö°¡ Á¦½ÃµÇ¾úÀ¸³ª °áÁ¤ÀûÀÎ °ÍÀº ¾ø´Ù. ¿ª»çÀûÀ¸·Î º¼ ¶§ J.F. ´Ù´Ï¿¤ ¸®°¡ Á¦Ã¢Çϰí J.D. ·Î¹öÆ®½¼¿¡ ÀÇÇØ ¼öÁ¤µÈ ´ÜÀ§¸· ¸ðµ¨ÀÌ ÀÖÀ¸¸ç, ±× ÈÄ B. º¥¼Õ µî¿¡ ÀÇÇØ Á¦Ã¢µÈ ¹Ýº¹ ´ÜÀ§ ¸ðµ¨ÀÌ ÀÖ´Ù. ÇöÀç ³Î¸® ÀÎÁ¤¹Þ°í ÀÖ´Â °ÍÀ¸·Î´Â 1972³â S.J. ½Ì°Å µîÀÌ Á¦Ã¢ÇÑ À¯µ¿ ¸ðÀÚÀÌÅ© ¸ðµ¨ÀÌ ÀÖ´Ù. ¸·ÀÇ ÁÖ ¼ººÐÀº ´Ü¹éÁú°ú ÁöÁúÀÌ¸ç µÎ ¼ººÐÀÇ Áß·®ºñ´Â 3:2~3:1·Î ´Ü¹éÁúÀÌ ¸¹´Ù. ÁöÁúÀÇ ÁÖ ¼ººÐÀº ÀÎÁöÁúÀÌ¸ç »ýü¸·ÀÇ ¼ººÐÀ¸·Î ´Ù´ç·ùµµ ¾à°£ Á¸ÀçÇÑ´Ù. ¸·ÀÇ ±¸¼º ¼ººÐÀÎ ÀÎÁöÁú ºÐÀÚ´Â ÀϺκп¡ Ä£¼ö¼º±â¸¦ °¡Áø °¡´À´Ù¶õ ºÐÀڷμ­, ±× ±ä ÃàÀÌ ¸·¸é°ú Á÷°¢À¸·Î ´Ã¾î¼­ ÀÖ°í ¼Ò¼ö¼º ºÎºÐÀÌ ¸¶ÁÖº¸°í ÀÖ¾î 2ºÐÀÚ µÎ²²ÀÇ ¸·À» ¸¸µç´Ù. ´Ü¹éÁúÀº ÁÖ·Î ±¸»ó ´Ü¹éÁúÀ̸ç, ÀÌ ÁöÁú ÀÌÁßÃþ ¼Ó¿¡ ´Ü¹éÁúÀÇ ¼Ò¼ö¼º ºÎºÐÀÌ Àá°Ü ÀÖµíÀÌ Á¸ÀçÇÑ´Ù. ¾î¶² °ÍÀº ¸·ÀÇ ¾ç¸é¿¡ ºÐÀÚÀÇ ÀϺκÐÀ» µå·¯³»°í ÀÖ´Ù. ÀÌ °á°ú ¸·Àº ÁöÁú°ú ´Ü¹éÁúÀÌ ¸ðÀÚÀÌÅ© »óÀ¸·Î Á¸ÀçÇÏ´Â ±¸Á¶°¡ µÈ´Ù. ÁöÁúÀº »ý¸®Àû ¿Âµµ¿¡¼­´Â ¾×üÀ̱⠶§¹®¿¡ ¸· ¼ººÐÀÎ ´Ü¹éÁúÀº ºñ±³Àû ÀÚÀ¯·Ó°Ô ¸·³»¸¦ À̵¿
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
biological products Complex pharmaceutical substances, preparations, or agents of organic origin, usually obtained by biological methods or assay, that depend for their action on the processes affecting immunity. They are used especially in diagnosis and treatment of disease (as vaccines or pollen extracts). Biological products are differentiated from biological factors in that the latter are compounds with biological or physiological activity made by living organisms.
(12 Dec 1998)
American Law Institute formulation Used in certain jurisdictions to determine criminal responsibility in legal proceedings.
See: criminal insanity.
(05 Mar 2000)
American Law Institute rule A test of criminal responsibility (1962): "a person is not responsible for criminal conduct if at the time of such conduct as a result of mental disease or defect he lacks substantial capacity either to appreciate the wrongfulness of his conduct or to conform his conduct to the requirements of law."
(05 Mar 2000)
national institute for occupational safety and health An institute of the centres for disease control and prevention which is responsible for assuring safe and healthful working conditions and for developing standards of safety and health. Research activities are carried out pertinent to these goals.
(12 Dec 1998)
national institute of mental health A component of the national institutes of health concerned with research, overall planning, promoting, and administering mental health programs and research.
(12 Dec 1998)
institute 1. The act of instituting; institution. "Water sanctified by Christ's institute."
2. That which is instituted, established, or fixed, as a law, habit, or custom.
3. Hence: An elementary and necessary principle; a precept, maxim, or rule, recognised as established and authoritative; usually in the plural, a collection of such principles and precepts; especially, a comprehensive summary of legal principles and decisions; as, the Institutes of Justinian; Coke's Institutes of the Laws of England. Cf. Digest, "They made a sort of institute and digest of anarchy." (Burke) "To make the Stoics' institutes thy own." (Dryden)
4. An institution; a society established for the promotion of learning, art, science, etc.; a college; as, the Institute of Technology; also, a building owned or occupied by such an institute; as, the Cooper Institute.
5. The person to whom an estate is first given by destination or limitation. Institutes of medicine, theoretical medicine; that department of medical science which attempts to account philosophically for the various phenomena of health as well as of disease; physiology applied to the practice of medicine.
Origin: L. Institutum: cf. F. Institut. See Institute, &.
Source: Websters Dictionary
(01 Mar 1998)
institute of medicine Identifies, for study and analysis, important issues and problems that relate to health and medicine. The institute initiates and conducts studies of national policy and planning for health care and health-related education and research; it also responds to requests from the federal government and other agencies for studies and advice.
(12 Dec 1998)
blood products Biopharmaceutical products purified from human blood, such as the blood clotting factor VIII used to treat haemophiliacs. (Recombinant factor VIII is also on the market.) The term also refers to biopharmaceuticals that act on blood or the cells that make blood. These products are often produced by the cells themselves, but in such tiny amounts that extracting them from blood is impractical, and so they are genetically engineered.
(14 Nov 1997)
gene products, env Retroviral proteins, often glycosylated, coded by the envelope (env) gene. They are usually synthesised as protein precursors (polyproteins) and later cleaved into the final products by a viral protease.
(12 Dec 1998)
gene products, gag Proteins coded by the retroviral gag gene. The products are usually synthesised as protein precursors or polyproteins, which are then cleaved by viral proteases to yield the final products. Many of the final products are associated with the nucleoprotein core of the virion. Gag is short for group-specific antigen.
(12 Dec 1998)
gene products, nef Products of the HIV nef gene (formerly 3'-orf gene). The products trans-suppress viral replication and function as negative regulators of transcription. Nef stands for negative factor.
(12 Dec 1998)
gene products, pol Retroviral proteins coded by the pol gene. Often synthesised as a gag-pol fusion protein (fusion proteins, gag-pol) and later cleaved into final products that include reverse transcriptase, endonuclease/integrase, and viral protease. Pol is short for polymerase, the enzyme class of reverse transcriptase.
(12 Dec 1998)
gene products, rev Trans-acting nuclear proteins whose functional expression are required for HIV viral replication. Specifically, the rev gene products are required for processing and translation of the HIV gag and env mRNAs, and thus rev regulates the expression of the viral structural proteins. Rev can also regulate viral regulatory proteins. A cis-acting antirepression sequence (car) in env, also known as the rev-responsive element (rre), is responsive to the rev gene product. Rev is short for regulator of virion.
(12 Dec 1998)
gene products, rex Post-transcriptional regulatory proteins required for the accumulation of mRNAs that encode the gag and env gene products in HTLV-I and HTLV-II. The rex (regulator x; x is undefined) products act by binding to elements in the ltr.
(12 Dec 1998)
gene products, tat Trans-acting transcription factors. Nuclear proteins whose expression is required for HIV viral replication. The tat protein stimulates HIV-ltr-driven RNA synthesis for both viral regulatory and viral structural proteins. Tat stands for trans-activation of transcription.
(12 Dec 1998)
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 1 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¾¾µðÁ¦¹Ú½ºÁÖ - »õâ
Chengdu Institute of Biological Products
Attenuated Japanese encephalitis virus
Àü¹®ÀǾàǰ | ºñ±Þ¿©
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • biological
    »ý¹°ÇÐÀÇ
  • biological
    »ý¹°ÇлóÀÇ;»ý¹°ÇÐÀÇ;»ý¹°ÇÐÀÀ¿ëÀÇ
  • dairy products
    ³«³ó Á¦Ç°;À¯Á¦Ç°
  • marine products
    ÇØ»ê¹°
  • primary products
    ³ó»ê¹°
  • relative biological effectiveness
    »ý¹°ÇÐÀû È¿°úºñ;»ý¹°È¿°úºñ
  • institute
    Á¦Á¤ÇÏ´Ù
  • Hudson Institute
    Çãµå½¼ ¿¬±¸¼Ò(h,KahnÀÌ ¼³¸³(1961)ÇÑ ¹Ì·¡ ¿¹Ãø;ºÐ¼®À» ÇÏ´Â µÎ³ú Áý´Ü)
  • International Institute for Strategic Studies
    (¿µ)±¹Á¦ Àü·«¿¬±¸¼Ò(I.I.S.S)
  • Massachusetts Institute of Technology
    ¸Å»çÃß¼¼Ã÷ °ø°ú ´ëÇÐ(»ç¸³ ´ëÇÐ)
  • institute
    ¼¼¿ì´Ù;¼³¸³(Á¦Á¤)ÇÏ´Ù;(Á¶»ç,¼Ò¼ÛÀ»)½ÃÀÛÇÏ´Ù;ÀÓ¸íÇÏ´Ù;(Çмú,¹Ì¼úÀÇ)Çùȸ;ÇÐȸ;¿¬±¸¼Ò;(ÇÐȸµîÀÇ)ȸ°ü;(À̰ø°ú°èÅëÀÇ)Àü¹®Çб³;´ëÇÐ;(±³¿øµîÀÇ)°­½Àȸ;Áýȸ;±ÔÄ¢;°ü½À;¿ø¸®
  • research laboratory(institute)
    ¿¬±¸¼Ò
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á